Therefore, therapeutic targeting of epigenetic modifications (e.g., DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, etc.)are a promising avenue for BL [85]. The gene discussed is DNMT1; the disease is Burkitt lymphoma.